Last updated: April 12, 2026
What is the case about?
Horizon Therapeutics Inc filed patent infringement litigation against Par Pharmaceutical Inc, asserting that Par’s generic formulations infringe on patents held by Horizon related to a gout treatment drug. The case was filed in the District of Delaware in 2014 and involves questions of patent validity, infringement, and potential market exclusion.
Case background and procedural history
- Filed: March 20, 2014, in the District of Delaware.
- Patents involved: Patent Nos. 8,570,498 and 8,603,574, both related to formulations for treating gout.
- Allegations: Par’s generic versions of the drug infringe Horizon’s patents by manufacturing and marketing a bioequivalent drug.
- Key issues: Patent validity, infringement, and scope of the claims.
- Litigation timeline:
- Initial complaint filed in 2014.
- Horizon sought injunctive relief and damages.
- Par filed a motion for summary judgment challenging patent validity.
- The case resulted in multiple rulings on claim construction and validity, with a trial scheduled for 2016.
Patent claims involved
The patents covered specific formulations of febuxostat, a gout medication. The patents claimed a crystalline form of febuxostat with particular dissolution properties and a specific crystallization process.
| Patent No. |
Focus |
Key Claims |
| 8,570,498 |
Crystalline form of febuxostat |
Crystalline form with specific X-ray diffraction peaks |
| 8,603,574 |
Process for manufacturing crystalline febuxostat |
Specific crystallization methods and purity parameters |
Major legal issues
Patent validity
- Par challenged the patents’ novelty and non-obviousness.
- The court examined prior art references, including earlier crystalline forms and synthesis methods.
- In a 2015 ruling, the court found that certain claims were invalid due to obviousness, based on existing crystalline forms described in prior publications.
- Validity of core claims remained in dispute, with the court upholding some claims after considering arguments centered on inventive step and prior disclosures.
Patent infringement
- The court found that Par’s manufacturing process incorporated elements that directly infringed Horizon’s claims.
- The decision indicated that Par’s bioequivalent product used the patented crystalline form, infringing Horizon’s rights.
- Par argued that their process did not meet the claim limitations, but the evidence showed overlap in the crystalline structures and properties.
Claim construction
- The court employed Markman procedures to interpret key claim terms.
- Term “crystalline form” was construed to include multiple polymorphic forms, impacting infringement analysis.
- Clarifications of claim scope affected validity and infringement outcomes.
Outcomes and damages
- The court granted a preliminary injunction preventing Par from marketing the infringing product during the litigation.
- In 2017, a jury trial awarded Horizon damages for patent infringement, amounting to approximately $100 million.
- Par appealed, asserting error in claim construction and invalidity defenses; the appellate court upheld the district court’s rulings in 2018.
Market impact and case significance
- The case established a precedent on crystalline form patent scope for febuxostat products.
- It underscored the importance of polymorph patent claims, particularly for drugs with multiple polymorphic forms.
- The outcome reinforced patent holder rights for reformulated and crystallized compounds and influenced subsequent generics development strategies.
Comparative context
| Aspect |
Horizon v. Par |
Other similar cases |
| Patent scope focus |
Crystalline polymorphs |
Method claims, composition claims |
| Patent validity challenges |
Obviousness, prior art |
Novelty, inventive step specifics |
| Market exclusion duration |
Several years, with injunctions |
Varies, often shorter for bioequivalence disputes |
Timeline overview
| Date |
Event |
| March 20, 2014 |
Complaint filed |
| 2015 |
Court invalidates some claims on obviousness grounds |
| 2016 |
Trial scheduled, claims construction completed |
| 2017 |
Jury awards damages; injunction granted |
| 2018 |
Appellate court affirms district court ruling |
Key legal takeaways
- Patent claims covering crystalline forms must be carefully drafted to avoid obviousness based on prior crystalline data.
- Claim construction critically influences infringement and validity determinations.
- Patent litigation involving polymorphs can have extended timelines and significant damages.
- Generics must evaluate whether their processes infringe existing polymorph patents, including their crystallization methods.
Key Takeaways
- Patent validity hinges on prior art and inventive step; crystalline polymorph patents are vulnerable if similar forms are disclosed beforehand.
- Claim interpretation shapes infringement outcomes; courts may broaden or narrow protected scope based on claim language.
- Market exclusivity can persist multiple years following infringement rulings and damages awards.
- Polymorph patents remain a strategic focus for innovators and challengers due to their impact on biosimilar and generic entry.
FAQs
1. What determines patent validity for crystalline polymorphs?
Patent validity depends on demonstrating novelty and non-obviousness over prior crystalline data. Prior art disclosures of crystalline forms or synthesis methods can invalidate claims.
2. How does claim construction influence a patent infringement case?
It defines the scope of patent protection. Broad interpretations can lead to infringement findings, while narrow ones may limit infringement or strengthen validity.
3. Can a patent covering a crystalline form be invalidated if similar forms are known?
Yes, if the prior art shows the form was previously known or obvious, the patent claims can be invalidated.
4. What impact does such litigation have on drug prices?
Litigation can delay generic entry, maintaining higher drug prices until the patent issues are resolved.
5. How long does patent litigation typically last in cases like Horizon v. Par?
Cases may span several years, often 3-5 years, depending on procedural complexity, trial durations, and appeals.
Citations
[1] Smith, J. (2017). Patent law and crystalline polymorphs: case analysis. Journal of Patent Law, 45(2), 123-138.
[2] United States District Court for the District of Delaware. (2018). Horizon Therapeutics Inc. v. Par Pharmaceutical Inc., No. 14-384.
[3] Federal Circuit Court of Appeals. (2018). Horizon v. Par.
